Chemical Abortion Risk Awareness Act
- Sponsor
- Rep. Stutzman, Marlin A. [R-IN-3]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jan 23, 2026
Bottom line
H.R. 7237 imposes new federal informed consent requirements and a 24-hour waiting period for chemical abortions performed by federally funded providers, backed by financial penalties and a private right of action.
What it actually does
This bill amends the Public Health Service Act to mandate new informed consent procedures for chemical abortion providers who receive federal funds. It requires providers to give women the full FDA-approved product label for abortion-inducing drugs, highlight warning sections, read these sections aloud, and obtain written confirmation at least 24 hours before the procedure. The bill also establishes a private right of action, allowing women or their parents to sue non-compliant providers for damages, and grants the Secretary of HHS authority to withhold federal funding from non-compliant entities.
Proponents argue
Proponents argue that this bill enhances patient safety by ensuring women receive comprehensive information about the risks of chemical abortions directly from FDA-approved sources. They contend that the mandated disclosures and 24-hour reflection period empower women to make fully informed decisions, addressing a perceived gap in current practices and holding providers accountable for thorough communication.
Opponents contend
Opponents argue that this bill imposes medically unnecessary and burdensome requirements on healthcare providers, creating significant barriers to accessing abortion care. They contend that existing informed consent processes are adequate and that the prescriptive nature of the bill, including the reading aloud of warning labels and the waiting period, is designed to deter women from seeking chemical abortions rather than genuinely inform them, potentially limiting access, especially for vulnerable populations.
The bill is concise and can be read quickly, allowing ample time for an informed reader to understand its provisions and implications.
Section 2, adding Title XXXIV, Section 3401 to the Public Health Service Act.
Definitions of Key Terms
This section defines critical terms used throughout the new title. It specifies 'chemical abortion' as the use of abortion-inducing drugs with the intent to cause the death of an unborn child, explicitly excluding treatments for ectopic/molar pregnancies or miscarriages, or preventing the mother's death. It also defines 'chemical abortion provider,' 'unborn child' as Homo sapiens at any stage prior to birth, and 'woman' as a human being with XX chromosomes.
Supporters argue
Proponents argue these definitions provide necessary clarity and precision, particularly in distinguishing abortion from other medical procedures and establishing a clear legal framework for the protection of unborn life and women's health. The specific definition of 'woman' ensures the bill's application is clear.
Critics contend
Opponents may argue that the definitions, particularly for 'chemical abortion' and 'unborn child,' are ideologically driven and could be interpreted to broaden the scope of restrictions beyond what is medically necessary or generally accepted. The definition of 'woman' as 'human being with XX chromosomes' is seen by some as exclusionary or medically inaccurate in certain contexts.
Tradeoffs
The definitions aim for legal clarity but also reflect a specific stance on the beginning of life and gender, which can be contentious in medical and legal contexts.
Section 2, adding Title XXXIV, Section 3402(a) to the Public Health Service Act.
Scope of Provider Compliance
This subsection mandates that any chemical abortion provider who receives federal funds, or works for an entity that receives federal funds, must comply with the bill's requirements. This compliance becomes effective 30 days after the bill's enactment.
Section 2, adding Title XXXIV, Section 3402(b) to the Public Health Service Act.
Enhanced Informed Consent Procedures
This section prohibits chemical abortions by covered providers unless, at least 24 hours prior, the provider gives the woman both electronic and paper copies of the full FDA-approved product label for each drug, with 'Warnings and Precautions' and 'Adverse Reactions' sections highlighted. The provider must also read these highlighted sections aloud to the woman and obtain her written confirmation that these steps were completed.
Section 2, adding Title XXXIV, Section 3402(c) to the Public Health Service Act.
Submission of Implementation Plan
Within 30 days of enactment, covered chemical abortion providers (or their employing entities) must submit a plan to the Secretary outlining how they will implement the new informed consent requirements.
Section 2, adding Title XXXIV, Section 3403 to the Public Health Service Act.
Federal Funding Sanctions for Non-Compliance
This section grants the Secretary the authority to withhold federal funding from any chemical abortion provider, or the entity employing them, found not to be in compliance with the bill's requirements. This authority applies 'notwithstanding any other law.'
Section 2, adding Title XXXIV, Section 3404 to the Public Health Service Act.
Private Right of Action for Violations
This section creates a private right of action, allowing a woman or her parent to sue a chemical abortion provider who violates the bill's requirements. Available relief includes objectively verifiable money damages for psychological and physical injuries, statutory damages equal to three times the cost of the abortion, and punitive damages. It also provides for attorney's fees for prevailing plaintiffs and for defendants if the suit is frivolous, explicitly stating no damages can be assessed against the woman.
Section 3
State Law Preemption Clarification
This section clarifies that the Act does not preempt any State law that establishes more extensive disclosure requirements regarding abortion or penalties for non-compliance. It ensures that states can maintain or enact stricter regulations than those outlined in this federal bill.
Defines 'woman' as 'a human being with XX chromosomes.'
Section 2, adding Title XXXIV, Section 3401(4) to the Public Health Service Act.
Why it matters:While definitions are standard, this specific phrasing is a deliberate choice with potential implications for how the bill applies to individuals who identify as women but may not have XX chromosomes, or for intersex individuals. It could be seen as an attempt to narrow the scope of who is protected or subject to the bill's provisions in a way that aligns with specific ideological viewpoints.
Case for: Proponents argue this provides clear, unambiguous biological criteria for who the bill's protections and requirements apply to, aligning with a traditional understanding of sex and reproduction.
Case against: Opponents argue this definition is exclusionary and potentially discriminatory against transgender men who may become pregnant, or intersex individuals, effectively denying them the bill's stated 'awareness' provisions or legal recourse. It could be seen as an attempt to legislate a specific biological definition of gender that does not encompass the full spectrum of human experience.
Estimated impact: Potentially affects a small but significant number of individuals seeking chemical abortions who do not identify as women or do not have XX chromosomes, potentially excluding them from the bill's protections or legal standing.